Protein tyrosine phosphorylation (PY) is a hallmark of sperm capacitation. In stallion sperm, calcium inhibits PY at pH ,7.8, mediated by calmodulin. To explore the mechanism of that inhibition, we incubated stallion sperm in media without added calcium, with calcium, or with calcium plus the calmodulin inhibitor W-7 (Ca/W-7 treatment). Treatment with inhibitors of calcium/calmodulin-dependent kinases, protein kinase A (PRKA), or Src family kinases suppressed the PY induced by the absence of added calcium, but not that induced by the Ca/ W-7 treatment, indicating that PY in the absence of added calcium occurred via the canonical PRKA pathway, but that PY in the Ca/W-7 treatment did not. This suggested that when calmodulin was inhibited, calcium stimulated PY via a noncanonical pathway. Incubation with PF-431396, an inhibitor of focal adhesion kinases (FAKs), a family of calcium-induced protein tyrosine kinases, inhibited the PY induced both by the absence of added calcium and by the Ca/W-7 treatment. Western blotting demonstrated that both FAK family members, protein tyrosine kinases 2 and 2B, were phosphorylated in the absence of added calcium and in the Ca/W-7 treatment, but not in the presence of calcium without calmodulin inhibitors. Inhibition of FAK proteins inhibited PY in stallion sperm incubated under capacitating conditions (in the presence of calcium, bovine serum albumin, and bicarbonate at pH .7.8). These results show for the first time a role for calcium/ calmodulin-dependent kinases in PRKA-dependent sperm PY; a non-PRKA-dependent pathway regulating sperm PY; and the apparent involvement of the FAK family of protein tyrosine kinases downstream in both pathways.
INTRODUCTION
The capacitation process in mammalian sperm is required for successful fertilization [1, 2] . One of the hallmarks of capacitation is an overall increase in protein tyrosine phosphorylation (PY) [3] . The cascade leading to increased PY appears to be initiated by the activation of the spermspecific soluble adenylyl (adenylate) cyclase (ADCY), resulting in an increase in intracellular levels of cAMP; this causes activation of the cAMP-dependent protein kinase A (PRKA), which leads via unknown mechanisms to an increase in phosphorylation of tyrosine residues of a wide range of proteins [4] .
Factors influencing sperm capacitation vary among species and have not yet been well delineated in the horse. Notably, the horse is one of the few domestic or laboratory species in which methods for effective in vitro fertilization have still not been established (reviewed in Hinrichs and Loux [5] ). The failure of equine in vitro fertilization to occur under conditions that are effective in other species implies differences in mechanisms for regulation of sperm capacitation in the stallion. However, stallion sperm have been found to undergo PY under appropriate conditions [6] [7] [8] . The cAMP/PRKA pathway appears to function in equine sperm, because PY can be increased by treatment with cAMP analogs or phosphodiesterase (PDE) inhibitors [9, 10] , and inhibition of PRKA activity by the specific inhibitors H-89 [9, 11] or PKI [12] abolishes the PY induced by capacitating conditions. The PY induced by capacitating conditions appears to be functional, because in one study, stallion sperm incubated under capacitating conditions were capable of fertilization in vitro when treated with procaine to induce hyperactivated motility [13] .
We recently reported that environmental pH had a profound effect on PY of stallion sperm: in standard capacitating media (containing calcium, bicarbonate, and bovine serum albumin [BSA] ), a marked increase in PY did not occur until the environmental pH approached 8 [7] . Surprisingly, at lower pH values (pH ;7.4), the presence of calcium in the medium potently inhibited PY [7] . This may be a species-specific finding; although calcium has been shown to have a moderate inhibitory effect on PY in human sperm [14, 15] , it does not inhibit sperm PY in the boar [16] or bull [17] , and it directly activates ADCY in mouse sperm [18] . We found that the suppressive effect of calcium on PY in stallion sperm at low pH appeared to be mediated by calmodulin (CALM), because treatment with the CALM inhibitor W-7 resulted in recovered PY under these conditions [7] . To the best of our knowledge, this was the first report of involvement of CALM in PY signaling in sperm, because inhibitors of CALM do not increase PY in mouse or ram sperm under capacitating conditions [19, 20] .
There is little information available regarding the pathway by which the increased activity of PRKA, a serine-threonine kinase, results in increased sperm PY in any species. Recent studies indicate that the Src family of tyrosine kinases (SFK) may modulate PY in human and mouse sperm [21] [22] [23] , because incubation of sperm in the presence of SU6656, a specific SFK inhibitor, caused a profound decrease in PY [21] [22] [23] [24] [25] . However, the mechanisms by which SFK regulate PY are not clear: although some studies in human and mouse sperm report that PRKA interacts with c-src tyrosine kinase, resulting in its phosphorylation [21] [22] [23] , Varano et al. [24] did not find this interaction in human sperm. An alternative regulatory mechanism has been postulated by Krapf et al. [25] : SFKs appear to exert their effect via suppression of serine-threonine phosphatases that regulate phosphorylation of PRKA substrates, rather than being effectors of PY downstream of PRKA (review in Visconti et al. [26] ). Other than a brief report confirming the suppressive effect of SFK inhibitors on PY [27] , essentially no information is available on tyrosine kinases involved in the PY pathway in stallion spermatozoa.
The objective of the present work was to study the roles of calcium and CALM in the regulation of PY in stallion sperm, in an attempt to determine the protein targets that may be directly related to sperm PY in this species.
MATERIALS AND METHODS

Materials
Triton X-100, SDS, BSA, 1-methyl-3-isobutylxanthine (IBMX), SU6656, and PF-431396 were purchased from Sigma-Aldrich Inc. (St. Louis, MO). Acrylamide, ammonium persulfate, 2-mercaptoethanol, Tween 20, and DC Protein Assay were purchased from Bio-Rad (Hercules, CA). Protease inhibitor cocktail tablets (Complete EDTA-free) were obtained from Roche (Basel, Switzerland). Anti-phosphotyrosine monoclonal antibody (clone 4G10) and polyvinylidene fluoride (PVDF) membrane were from Millipore (Billerica, MA). Anti-b-actin monoclonal antibody was purchased from Abgent (San Diego, CA). Anti-PTK2 (pY397) and anti-PTK2B (pY402) were purchased from Life Technologies Corporation (Camarillo, CA). Anti-mouse immunoglobulin G (IgG) and anti-rabbit IgG horseradish peroxidase-conjugated secondary antibodies, and anti-mouse IgG fluorescein isothiocyanate (FITC)-conjugated secondary antibody were from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). Slowfade gold antifade was from Molecular Probes (Eugene, OR). Enhanced chemiluminescence detection reagents and Hyperfilm ECL were obtained from Amersham (Arlington Heights, IL). W-7, deltamethrin, KN-93, PKI, okadaic acid, genistein, and GF-109203X were purchased from Enzo Life Sciences (Farmingdale, NY).
Media
The basal medium used was modified Whitten (MW) media, consisting of 100 mM NaCl, 4.7 mM KCl, 1.2 mM MgCl 2 , 5.5 mM glucose (anhydrous), 22 mM HEPES, 2.4 mM sodium lactate, and 1.0 mM pyruvic acid. Medium with bicarbonate was prepared by adding 25 mM NaHCO 3 (MWþBic). For some media, 2.4 mM calcium chloride was added (MWþBicþCa). Medium containing calcium, bicarbonate, and BSA was designated MWþþþ. All media were adjusted with NaCl to an osmolality of 290-300 mOsm/kg; pH was adjusted to 7.25 using NaOH 1 M. Bicarbonate was added 1 h prior to the experiment, and the medium was maintained at 378C until the beginning of the experiment, at which time the pH was checked again and adjusted if necessary.
Semen Collection and Processing
Semen was collected from three fertile stallions using an artificial vagina (Missouri Model AV; Nasco, Ft. Atkinson, WI). A nylon inline filter (Animal Reproduction Systems, Chino, CA) was used to eliminate the gel fraction. The sperm-rich fraction was diluted 1:5 (v/v) in MW medium. The sperm suspension was centrifuged at 400 3 g for 10 min at room temperature (228C-248C), and then the supernatant was transferred to a 15-ml conical tube and centrifuged again at 400 3 g for 10 min at room temperature. The sperm concentration was then determined using a NucleoCounter SP-100 (Chemometec, Allerød, Denmark) and adjusted to a final concentration of 10 3 10 6 or 30 3 10 6 spermatozoa per milliliter. If addition of inhibitors was required, the MW was supplemented with the designated treatment prior to sperm dilution. Aliquots of the final sperm suspension were placed in 5-ml round-bottom plastic tubes from BD Falcon (San Jose, CA 
Western Blotting
After 4 h, the sperm were processed as described by Gonzalez-Fernandez et al. [7] . In brief, sperm were centrifuged at 5000 3 g for 3 min at room temperature and washed in PBS at 48C supplemented with the protein tyrosine phosphatase inhibitor sodium orthovanadate (0.2 mM). After centrifugation, the supernatant was removed, and the pellet was resuspended at room temperature in lysis buffer consisting of 62.5 mM Tris-HCl, pH 6.8; 25% glycerol; 2% SDS; 0.01% Bromophenol Blue [28] ; and a protease inhibitor cocktail (Complete EDTA free; Roche). Samples were then centrifuged at 10 000 3 g for 10 min at 48C, and the protein concentration of the supernatant was determined using a Bio-Rad DC Protein Assay according to the manufacturer's instructions. After protein determination, 2-mercaptoethanol (2.5%) was added to the lysates before heating for 5 min at 958C. Aliquots of lysates containing the designated amount of protein (15 lg) were loaded in 10% polyacrylamide gels and separated according to their molecular weight by SDS-PAGE electrophoresis. The proteins were then transferred to Immobilon-P PVDF membranes (Millipore). Membranes were blocked for 1 h at room temperature using 3% BSA in a Tris-buffered saline-Tween 20 solution (TBS-T) containing 20 mM Tris/HCl, pH 7.5; 500 mM NaCl; and 0.1% (v/v) Tween 20. Immunodetection of tyrosine-phosphorylated proteins was performed using the anti-phosphotyrosine monoclonal antibody diluted 1:5000 in 3% BSA in TBS-T for 60 min at room temperature. For the anti-phospho PTK2B Tyr 402 antibody, the membranes were blocked in 5% milk in TBS-T for 60 min at room temperature, and the antibody was diluted 1:5000 in 5% milk in TBS-T; the membranes were incubated with the antibody overnight at 48C. For the antiphospho PTK2 Tyr 397 antibody, the membranes were blocked in 3% BSA in TBS-T for 60 min at room temperature, and the antibody was diluted 1:1000 in 3% BSA in TBS-T buffer; the membranes were incubated with the antibody overnight at 48C. As a loading control, the constitutive b-actin protein was used; the designated membranes were incubated using a primary anti-b-actin antibody diluted 1:5000 (v/v) in 3% BSA in TBS-T at 48C overnight. After incubation with the primary antibody, membranes were washed 10 min with TBS-T. Then, the membranes were incubated for 45 min at room temperature with a secondary anti-mouse antibody (for anti-PY and b-actin) or anti-rabbit (anti-PTK2 and anti-PTK2B) conjugated to horseradish peroxidase-coupled IgG antibodies diluted 1:5000 in their respective blocking buffers at room temperature for 45 min. Following secondary antibody incubation, all membranes were washed for 30 min, then incubated for 5 min with the ECL Kit (Amersham) and exposed to Hyperfilm ECL film.
Immunofluorescence
Following incubation, sperm were centrifuged 3 min at 5000 3 g and washed with 1 ml of PBS. After centrifugation the pellet was resuspended in 1 ml of PBS, and the cell concentration was adjusted to 5 3 10 6 spermatozoa per milliliter. A total of 10 ll of the sample was placed on a slide pretreated with poly-L-lysine. After 10 min, spermatozoa were fixed with 4% formaldehyde in PBS for 15 min at room temperature and permeabilized with 0.1% Triton X-100 (v/v) in PBS for 10 min. After three washes with PBS, sperm were blocked with 3% BSA in PBS for 60 min. Primary incubation with anti-phosphotyrosine monoclonal antibody (diluted 1:500) was performed in 3% BSA in PBS at 48C overnight. The sample was then washed with PBS and incubated with antimouse IgG (FITC)-conjugated secondary antibody in 3% BSA in PBS for 1 h at room temperature. After three washings with PBS, the samples were mounted on a slide with Slowfade gold antifade solution from Molecular Probes following the manufacturer's indications. The control samples were processed as described above, but lacking primary antibody. Samples were evaluated using an Olympus BX60 fluorescence microscope (New Hyde Park, NY) equipped with a 403 objective.
Sperm Motility
Sperm motility was evaluated using computer-assisted sperm analysis. After sperm incubation, 6 ll of each sperm sample was placed in a warmed (378C) counting chamber with a fixed height of 20 lm (Leja Standard Count 2 Chamber slides; Leja Products B.V., Nieuw-Vennep, The Netherlands). The slide was inserted into the computerized sperm motion analyzer (IVOS version GONZÁ LEZ-FERNÁ NDEZ ET AL.
12.2L; Hamilton Thorne Biosciences, Beverly, MA) equipped with a stage set at 378C, and the total motility was evaluated. A minimum of 10 microscopic fields were evaluated.
Viability Assay
Sperm viability was determined using a NucleoCounter SP-100 (Chemometec) according to the manufacturer's instructions, as previously validated [29] . The total sperm concentration was determined by diluting 10 ll of sperm solution with 1 ml of detergent reagent S100, and the product was loaded into a cassette containing propidium iodide (PI). The sample was analyzed, and the total number of cells was obtained. Sperm viability was assessed by diluting 20 ll of the sperm sample with PBS (200 ll) at pH 7.1, placing this in the PIcontaining cassette, and analyzing it with the NucleoCounter set for this dilution, thus determining the number of nonviable cells. The percentage of viable sperm was determined by subtracting the nonviable cells from the total number of cells.
Statistical Analysis
The data were first examined using the Kolmogorov-Smirnov test to determine their distribution. In view of the Gaussian distribution of the data, differences in the motility and viability parameters among treatments were determined by a one-way ANOVA. Statistical significance was set at P , 0.05. Analyses were performed using SigmaPlot version 12.0 for Windows (Systat Software, Chicago, IL).
RESULTS
Effect of Calcium and W-7 on PY
Stallion sperm (n ¼ 3, one ejaculate per stallion) were incubated in air in MW medium with 25 mM bicarbonate (MWþBic) with no added calcium or with 2.4 mM calcium (MWþBicþCa; pH 7.25), at 378C for 4 h at 30 3 10 6 spermatozoa per milliliter in a volume of 1 ml. This concentration of sperm causes the medium to remain at a low pH (,7.5) during incubation [7] . Bovine serum albumin was eliminated from the medium because it exerts a non-calciumrelated inhibition of PY in stallion sperm at lower pH [7] .
To study the effect of CALM on the calcium-mediated inhibition of PY, sperm were incubated in the presence or absence of added calcium, or with calcium plus 200 lM CALM inhibitor, W-7. Under these conditions, as we have shown previously [7] , presence of calcium was associated with a profound inhibition of PY, and this was reversed by treatment with W-7 ( Fig. 1) . We then performed in situ immunofluorescence to localize tyrosine-phosphorylated proteins in sperm incubated under these conditions. When sperm were incubated in the absence of added calcium (MWþBic), PY was observed along the entire tail, with an area of reduced fluorescence near the distal end of the midpiece (Fig. 2, A and B) . The same pattern of immunofluorescence was observed in sperm incubated in MWþBicþCa in the presence of W-7 ( 
Effect of Inhibitors of CALM Targets on PY
The rescue of PY by W-7 suggests that the suppressive action of calcium on PY is modulated through CALM. To explore the pathway involved in the calcium-CALM-associated inhibition of PY, we investigated the specific CALM targets: calcineurin (a serine/threonine phosphatase), calcium/CALMdependent kinases (CAMKs; serine/threonine kinases), and calcium-CALM-dependent PDEs [30] . Calcineurin and PDEs have previously been implicated in calcium-associated reduction in PY in human sperm [31, 32] . Stallion sperm were processed (n ¼ 3, one ejaculate per stallion) as for the previous experiment, and they were incubated in air at 378C for 4 h in the presence of calcium and the calcineurin inhibitor deltamethrin; the inhibitor of CAMKs (CAMK1, CAMK2, and CAMK4) KN-93; okadaic acid, the specific inhibitor of protein phosphatase type 1 (PPP1) and type 2A (PPP2A); or the nonselective PDE inhibitor IBMX. These inhibitors were used at concentrations shown to be effective in other species [17, 25, 31, [33] [34] [35] [36] [37] [38] [39] . None of these inhibitors recovered the PY observed in medium without added calcium (Fig. 3) . Notably, treatment with the CAMK inhibitor KN-93 appeared to result in an increased suppression of PY compared with the 2.4 mM calcium treatment alone (Fig. 3, lanes 6-8 vs. lane 2) . These results indicated that the suppression of PY by calcium-CALM was not occurring via increased serine/threonine phosphatase activity downregulating PRKA (failure of inhibitors of calcineurin, CAMKs, and general phosphatases to rescue PY) or through increased PDE activity yielding lower levels of cAMP and thus decreasing PRKA activity (failure of IBMX to rescue PY). 
PROTEIN TYROSINE PHOSPHORYLATION IN STALLION SPERM
Effect of KN-93 on PY
To explore whether treatment with the CAMK inhibitor KN-93 had a suppressive effect on PY, as suggested in the presence of calcium (Fig. 3 ), sperm were incubated with different concentrations of KN-93 (12.5, 25, and 50 lM) in MWþBic without added calcium (n ¼ 3, one ejaculate per stallion). KN-93 consistently inhibited PY in a dose-dependent manner (Fig. 4) , suggesting that inhibition of CAMKs was associated with a reduction in PY.
Effect of Inhibition of CAMKs and PRKA on PY in the Presence of W-7
Next, we explored the roles of PRKA and CAMKs in PY induced in the absence of added calcium, and in PY induced in GONZÁ LEZ-FERNÁ NDEZ ET AL. the presence of calcium but with suppression of calcium-CALM. Sperm were processed as above and were incubated in MWþBic in the absence of added calcium or in the presence of calcium and W-7, with 50 lM PKI (a specific PRKA inhibitor previously shown to effectively inhibit PY at concentrations of 40 and 60 lM in stallion sperm) [12] or 25 lM KN-93 added (n ¼ 3, one ejaculate per stallion). The addition of 50 lM PKI or 25 lM KN-93 inhibited the PY seen in the absence of added calcium (Fig. 5, lanes 4 and 5 vs. lane 1) ; however, these inhibitors had little effect on the PY seen in the presence of calcium and W-7 (Fig. 5, lanes 6 and 7 vs. lane 3) . The suppressive effect of PKI suggests that the PY seen in the absence of added calcium is occurring via the canonical PRKA pathway, and that CAMKs may also have a role in this pathway. However, the PY occurring in the calcium-W-7 treatment (i.e., in the presence of calcium but absence of CALM activity) appears to be occurring via a different pathway.
Effect of Genistein, an Inhibitor of Protein Tyrosine Kinases, on PY
The results of the previous experiment (Fig. 5) indicated that PY occurring in the presence of calcium during CALM inhibition was not mediated through the canonical PRKA pathway. We then hoped to elucidate the role of specific kinases in both pathways. First, to confirm that both pathways involved protein tyrosine kinases, sperm were incubated in MWþBic without added calcium or in the presence of added calcium and W-7, and were treated with a broad range of doses of genistein, a general protein tyrosine kinase inhibitor used in human sperm at 400 lM [40] . The results showed that genistein completely inhibited the PY induced both by the absence of added calcium and by treatment with W-7 in the presence of calcium, in a dose-dependent fashion (Fig. 6A) , indicating that both pathways are dependent upon activity of protein tyrosine kinases.
Effect of SU6656, a Selective SFK Inhibitor, on PY
The following experiments were designed to test the role of specific proteins in the PY occurring via the two apparently different pathways: in the absence of added calcium, and in the presence of calcium but suppression of CALM. The most important protein tyrosine kinase family implicated in PY in sperm is the SFK [21] [22] [23] [24] [25] . In this experiment, the possible role of SFK proteins in the regulation of PY via both pathways was tested. For this purpose, different concentrations of the SFK inhibitor SU6656 (1, 5, 10, and 25 lM) were used, because these concentrations have been shown to be effective in inhibiting PY in mouse sperm [25] . Sperm were incubated in MWþBic in the absence of added calcium or in the presence of calcium and W-7. Treatment with SU6656 completely inhibited the PY mediated by the absence of added calcium, but not that found in the presence of calcium and W-7 (Fig. 7) . Because SFKs are known to be involved in PRKA-mediated PY [21] [22] [23] , this result further supports the hypothesis that the PY observed in the absence of added calcium (designated [À]Ca) occurs via the canonical PRKA pathway, whereas the increase in PY observed when CALM is inhibited in the presence of calcium (designated Ca/W-7) occurs through a different pathway.
Effect of GF-109203X, a Selective PRKC Inhibitor, on PY One interpretation of the differences seen between the [À]Ca and the Ca/W-7 treatments is that calcium-CALM inhibits the canonical PRKA pathway, but that in the absence of active CALM, calcium stimulates an alternative pathway. One candidate that could be mediating this effect is protein kinase C (PRKC), a serine/threonine kinase regulated by calcium [41] . 
PROTEIN TYROSINE PHOSPHORYLATION IN STALLION SPERM
Activation of this protein induces an increase in the percentage of capacitated sperm in mice [42, 43] , and it is also involved in the regulation of the acrosome reaction in human and stallion sperm [44, 45] . To explore this hypothesis, different concentrations of the PRKC inhibitor GF-109203X (500 nM, 1 lM, and 10 lM) were tested under the two treatment conditions ([À]Ca and Ca/W-7). The PRKC inhibitor GF-109203X is effective in suppressing cBiMPS-induced hyperactivation at concentrations of 25 and 50 lM in boar sperm [46] . Treatment with GF-109203X inhibited the PY seen in the absence of added calcium at the highest dose tested, which has also been shown to inhibit PRKA (reviewed in Petrunkina et al. [47] ), but did not inhibit the PY associated with treatment with calcium and W-7 at any dose (Fig. 8) .
Effect of PF-431396, a Selective FAK Family Inhibitor, on PY
To explore the possible mechanism for the PY found in the Ca/W-7 treatment, we searched for protein tyrosine kinases that were activated by calcium. In this light, we identified the focal adhesion kinase (FAK) family. This family has two members: protein tyrosine kinase 2 (PTK2; previously known as focal adhesion kinase 1 [FAK1]) and protein tyrosine kinase 2 beta (PTK2B; previously known as focal adhesion kinase 2 [FAK2] or proline-rich tyrosine kinase 2 [PYK2]). These proteins are activated by calcium or calcium-binding proteins [48, 49] , and have been shown to regulate a variety of processes, including cell migration and cytoskeleton function, in somatic cells [50] .
To the best of our knowledge, no information is available on the presence or function of PTK2 in sperm of any species. In one report, PTK2B was found in the tail and acrosomal regions of mouse spermatozoa, as detected by immunocytochemistry, and treatment with calcium ionophore resulted in increased PTK2B phosphorylation [51] . To determine whether FAK family proteins were involved in PY in stallion spermatozoa, we evaluated the effect of different concentrations (1, 5, and 10 lM) of a specific FAK inhibitor (PF-431396) [52] on PY in the [À]Ca and Ca/W-7 treatments. Use of PF-431396 at 3 lM effectively suppressed PYK2 activity in transfected NIH3T3 cells [53] . Treatment with PF-431396 consistently inhibited the increase in PY induced by the absence of added calcium and induced by W-7 in the presence of calcium (Fig. 9) .
Effect of PF-431396, a Selective FAK Family Inhibitor, on PTK2 and PTK2B Phosphorylation in Stallion Sperm
We next studied the phosphorylation of FAK family proteins in stallion sperm under different conditions to confirm that these proteins were present in stallion spermatozoa and that their phosphorylation was inhibited by PF-431396. There are numerous sites of phosphorylation implicated in the regulation of PTK2 and PTK2B, and in their interaction with other proteins, the most important being the autophosphorylation residues [54] . The activity of FAK family proteins in stallion sperm was studied using phospho-specific antibodies against these residues: tyrosine 397 for PTK2 and tyrosine 402 GONZÁ LEZ-FERNÁ NDEZ ET AL.
for PTK2B. PTK2 and PTK2B were phosphorylated in both [À]Ca and Ca/W-7 treatments. Treatment with PF-431396 completely inhibited phosphorylation of both proteins (Fig.  10) .
Effect of FAK Inhibitors on PY in Stallion Sperm Incubated under Capacitating Conditions
To determine whether FAK family proteins were involved in physiological capacitation of equine sperm-that is, induction of PY in the presence of bicarbonate, BSA, and calcium (shown to be compatible with fertilization after treatment of sperm to induce hyperactivated motility [13] )-the effect of the FAK inhibitor (PF-431396) on PY was studied in sperm incubated in capacitating conditions: MW with 7 mg/ ml BSA, 2.4 mM calcium, and 25 mM bicarbonate in 0.5 ml at 10 3 10 6 /ml [6, 7, 9, 55] at various pH levels. Treatment with PF-431396 consistently inhibited the increase in PY associated with incubation under capacitating conditions (pH 7.9 and pH 8.5; Fig. 11 ). GONZÁ LEZ-FERNÁ NDEZ ET AL.
Effect of Inhibitors Used on Sperm Motility and Viability
All of the inhibitors used above were evaluated to determine their effect on sperm motility, and those inhibitors associated with a decrease in motility were further evaluated to determine their effect on sperm viability (membrane integrity) via exclusion of PI. Total motility in sperm treated with inhibitors was compared with that for sperm in the same medium but without inhibitor. There was no significant effect on total sperm motility of deltamethrin at 1 nM to 1 lM; KN-93 at 12.5 to 50 lM; okadaic acid at 1 nM to 1 lM; IBMX at 1 and 3 mM; PKI at 50 lM; genistein at 10 to 800 lM; SU6656 at 1 to 25 lM; GF-109203X at 0.5 to 10 lM; or PF-431396 at 1 to 10 lM. Treatment with W-7 at 200 lM was associated with a significant decrease in total motility (19.5% 6 2.9%, vs. 77.3% 6 3.3% for control; mean 6 SEM), as previously reported by Lasko et al. [56] Sperm viability (PI exclusion) was evaluated in sperm treated with W-7, because it was associated with suppression of motility, and sperm treated with genistein, because of the high doses of this compound used (up to 800 lM). Spermatozoal viability was not significantly different from that for control for W-7 (200 lM) or for any dose of genistein tested (P . 0.05; Fig. 6B ).
DISCUSSION
The results of this study suggest that two separate pathways exist for induction of PY in stallion spermatozoa: the canonical PRKA pathway, which is inhibited by calcium in stallion sperm at low pH, and a pathway exhibited in the presence of calcium and inhibition of CALM at low pH, which appears to not involve PRKA. These two pathways appear to come together at the level of protein tyrosine kinases of the FAK family. The FAK proteins identified via these low-pH inhibition models play a role in the increase in PY in stallion spermatozoa under capacitating conditions (induction of PY in the presence of calcium and BSA, at high pH). Thus, in this study we have identified protein tyrosine kinases that appear to modulate the PY associated with sperm capacitation, downstream of PRKA.
The key roles of calcium and external pH in the induction of PY in stallion sperm have previously been described by our laboratory [7] . Sperm incubated in standard medium at pH ;7.4 in the presence of calcium showed essentially no PY; however, at high pH levels (7.8 and above), PY occurred in the presence of calcium. The effect of increased pH appeared to be physiological, because the environmental pH of stallion semen increased from a mean of 7.5 before insemination to a mean of 7.9 after insemination (fluid recovered from the estrus mare uterus 15 to 30 min after insemination of raw semen [7] ). We hypothesized that the inhibition of PY by calcium at low pH was a physiological mechanism to prevent premature capacitation. The present work was performed to unravel the pathways mediating the inhibition of PY by calcium at low pH.
As we showed previously [7] , the inhibiting effect of calcium at low pH can be reversed by inhibition of CALM. We hypothesized that the PY-inhibiting effect of calcium-CALM could be explained by a CALM-mediated increase in phosphatase activity, stimulation of PDE, or possibly by action of the major calcium-CALM-mediated kinases, CAMK1, CAMK2, and CAMK4. Calcineurin, a serine/threonine phosphatase, is regulated by CALM; the inhibition of this phosphatase has been reported to recover PY after calcium treatment in human sperm [31] . Binding of CALM to PDE causes an increase in esterase activity, resulting in a decrease in intracellular cAMP that causes diminished PRKA activity, and therefore diminished PY [57] . However, neither the inhibition of calcineurin (or of PPP1/PPP2A), nor the inhibition of PDE, nor the inhibition of CAMKs restored PY in the presence of calcium (Fig. 3) , suggesting that the inhibitory effect of calcium-CALM on PY is not occurring through these intermediaries. Similarly, Marin-Briggiler et al. [36] reported that KN-93 does not recover PY in the presence of calcium in human sperm.
Surprisingly, although inhibition of CALM restores PY in the presence of calcium, the inhibition of CAMKs seemed to further inhibit PY under these conditions (Fig. 3) . To test whether CAMKs stimulated PY in stallion sperm, we evaluated the effect of inhibition of CAMKs on the PY induced in the absence of added calcium (Fig. 4) . In these conditions, complete inhibition of PY was observed at 25 lM KN-93, indicating a core role for CAMKs in the regulation of PY in stallion sperm. To the best of our knowledge, this is the first time that CAMKs have been shown to play a role in the regulation of PY in sperm of any species.
CAMKs are, like PRKA, serine/threonine kinases. We explored the relative roles of CAMKs and PRKA in the regulation of PY in mammalian sperm, and the effect of CALM inhibition on these kinases (Fig. 5) . The inhibition of PRKA abolished the PY induced in the absence of added calcium, as 
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previously reported in stallion sperm under capacitating conditions [12] . However, the inhibition of PRKA did not inhibit the PY induced in the presence of calcium and the CALM inhibitor W-7. This suggested that in the Ca/W-7 treatment, PY occurred via a separate, non-cAMP/PRKAdependent pathway. Furthermore, inhibition of CAMKs reduced PY in the [À]Ca treatment but not the Ca/W-7 treatment, suggesting involvement of CAMKs in the canonical PRKA pathway but not in the alternative pathway.
The inferred activity of CAMKs in the absence of added calcium, and their opposite actions to those of CALM, suggest that their activity in this instance is not being regulated via the classical calcium-CALM-CAMKs cascade. Although CAMKs are CALM targets, it has been described that activation of CAMK2 can also occur by autophosphorylation at the threonine 286 residue, and this event can take place independently of CALM [58] . In addition, PRKA has been shown to modulate the activity of CAMK2 in cardiomyocytes [59] . The potential for PRKA activation of CAMK2 is supported by the fact that there are consensus domains for PRKA recognition in the CAMK2 sequence (NCBI Protein Database). Thus, it is possible that during capacitation PRKA is either responsible for ongoing phosphorylation of CAMK2 or initiates its phosphorylation, which is then maintained by autophosphorylation at the CAMK2 threonine 286 residue, resulting in its activation, as previously postulated [60] .
Inhibition of SFK also showed an inhibitory effect on PY in the [À]Ca treatment but not in the Ca/W-7 treatment. These results, and previous results reported by Krapf et al. [25] , suggest that SFKs are not the tyrosine kinases located downstream of PRKA. These authors postulated that SFKs inhibit serine-threonine phosphatases, possibly PPP2A, that apparently modulate PRKA activity by dephosphorylating PRKA substrates [25, 26] . This is compatible with our findings that the general tyrosine kinase inhibitor genistein abolished PY under both conditions (Fig. 6A ) without affecting sperm viability (Fig. 6B) , but the SFK inhibitor SU6656 (Fig. 7) inhibited PY only in the [À]Ca treatment.
Theoretically, removing calcium or adding W-7 in the presence of calcium should work identically, by inactivating CALM. However, the control of the PY achieved under these two conditions differed consistently in its sensitivity to factors affecting the cAMP/PRKA pathway. Because it is assumed that CALM is inactive in either treatment, the main difference between the two appears to be the presence of calcium. This suggests that calcium may be exerting two opposite effects on PY: an inhibitory effect via CALM, and a separate, stimulatory effect in the absence of CALM activity, on protein tyrosine kinases downstream of PRKA, SFK, or CAMKs.
Because PRKC is a serine/threonine kinase regulated by calcium, this kinase could be a plausible candidate for the calcium-induced increase in PY described above. PRKC activation has been shown to induce PY in other systems [61, 62] . However, inhibition of PRKC did not decrease PY in the Ca/W-7 treatment (Fig. 8) . The inhibition of PY induced by 10 lM GF-109203X in the [À]Ca treatment is likely due to the inhibition of PRKA attributed to this compound at concentrations higher than 2 lM, as reported by the manufacturer (www. enzolifesciences.com) and other authors [47] . This result reinforces the finding that PRKA is not implicated in the increase in PY in the Ca/W-7 treatment.
A search for calcium-responsive protein tyrosine kinases identified the FAK family [63] . This family is composed of two proteins: PTK2 (formerly FAK1) and PTK2B (formerly PYK2). PTK2B has been reported to be directly regulated by calcium in a wide range of cellular types [50] and has also been identified in murine spermatozoa [51] , whereas PTK2 has been shown to be regulated by a calcium-binding protein in platelets [48] . We found that inhibition of the FAK proteins by PF-431396 abolished PY induced in both the [À]Ca and the Ca/W-7 treatments (Fig. 9) . Western blotting confirmed the presence of phospho-FAK proteins in stallion spermatozoa and verified the inhibitory effect of PF-431396 on both PTK2 and PTK2B (Fig. 10) . Neither protein was phosphorylated in calciumcontaining medium in the absence of W-7, concomitant with the absence of PY in this treatment. Treatment with W-7 to inhibit CALM recovered the phosphorylation of both proteins FIG. 12. Diagram of proposed PY regulatory events in stallion sperm. During capacitation, bicarbonate activates ADCY, increasing the production of cAMP, which will directly activate PRKA. Phosphorylation of PRKA substrates is regulated by serine-threonine phosphatases (STPPs) that are inhibited by SFK. PRKA phosphorylates CAMK2, which will eventually activate FAK. Calcium has an inhibitory effect on PY mediated directly by CALM (solid line with arrow) and a stimulatory effect on PY mediated by FAK. Information in box is that suggested by Krapf et al. [25] .
in the presence of calcium, indicating a suppressive effect of CALM on these kinases. The action of FAK family proteins in both [À]Ca and Ca/W-7 treatments suggests that these proteins may be directly responsible for the increase in PY in stallion sperm during capacitation. Unfortunately, we were unable to demonstrate the nonphosphorylated form of the FAK proteins in equine sperm using available anti-human PTK2 or PTK2B antibodies (data not shown). This may be because these antibodies are raised against the more variable terminal regions of the proteins, whereas the phosphoprotein antibodies are produced against their highly conserved active domain. However, the clear effect of the specific FAK inhibitor PF-431396 (total inhibition of PY), together with the recognition of the active protein on Western blotting, indicates the presence and involvement of these kinases in stallion sperm capacitation.
Calmodulin and CAMKs appear to regulate FAK activity in other systems, although their roles are controversial. Calmodulin has been reported to activate PTK2B in human embryonic kidney cells, HeLa cultures, and mouse fibroblasts [64] ; however, in T-type lymphocytes, CALM inhibition by W-7 results in PTK2B activation [49] . It has been reported that PTK2B can be activated by CAMK2 in vascular smooth muscle cells [65] . We postulate that in stallion sperm, FAK may be activated by CAMK2 and inhibited by CALM. We propose that CAMK2 is a target of PRKA; thus, CAMK2 serves as a messenger between PRKA and FAK (Fig. 12) . Neither CAMK2 nor factors in the PRKA pathway seem to play a part in the PY occurring in the Ca/W-7 treatment (Figs. 5, 7, and 8); the reason for this is unclear, but it is possible that the PRKA pathway is sensitive to remaining CALM activity or is inhibited by calcium via non-CALM mechanisms. Thus, we postulate that FAK can be activated independently by CAMK2 or by calcium (directly or through another calcium-activated protein), and that FAK is the common point of the cAMP/ PRKA pathway and the calcium-stimulated pathway.
It appears likely that the cAMP/PRKA and calciumstimulated pathways regulate the same protein tyrosine kinases, because immunolocalization of tyrosine-phosphorylated proteins in sperm incubated in the two treatments showed the same pattern along the tail (Fig. 2) , and PY banding patterns for the [À]Ca and Ca/W-7 treatments were similar on Western blotting. We propose that the active pathway in the [À]Ca treatment is the PRKA pathway, terminating in activation of FAK, and that the pathway active in the Ca/W-7 treatment is direct calcium-mediated activation of FAK in the absence of active CALM. To the best of our knowledge this is the first time that FAKs have been implicated in the regulation of PY in the sperm of any species. It is tempting to speculate that the FAK may be the link between cAMP/PRKA activation and capacitation-related PY; however, given the wide variety of proteins that undergo PY under capacitating conditions and the fact that kinase specificity is crucial for selective cellular signaling, it may be that FAK activates other protein tyrosine kinases further down the pathway.
Much additional work is needed to define the modulation of PY mediated by calcium, cAMP/PRKA, and CAMKs; however, the present study opens a new door that will hopefully lead toward a better understanding of the control of PY in mammalian sperm.
